Indaptus Therapeutics, Inc.

As previously disclosed in the Current Report on Form 8-K filed by Indaptus Therapeutics, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on September 9, 2026, the Company entered into a Stock Purchase Agreement, dated September 8, 2026 (the “Purchase Agreement”) with the purchasers party thereto (the “Purchasers”), pursuant to which the Company agreed to issue and sell an aggregate of 20,338,974 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share, in a private placement (the “Private Placement”), for aggregate gross proceeds of approximately $24.0 million, before deducting offering expenses.

Subsequently, as reported in the Company’s Current Report on Form 8-K filed with the SEC on September 30, 2026, the Company and the Purchasers entered into notices and consents pursuant to which, among other things, the outside date applicable to each Purchaser under the Purchase Agreement was extended from September 29, 2026 to October 16, 2026.

Item 8.01. Other Events.

On October 16, 2026, the Company completed the Private Placement, having received the full purchase price from each of the Purchasers in accordance with the terms of the Purchase Agreement, as amended. In connection with the closing of the Private Placement, the Company will issue an aggregate of 20,338,974 Shares to the Purchasers.